Heck Capital Advisors LLC Invests $2.04 Million in Eli Lilly and Company (NYSE:LLY)

Heck Capital Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,645 shares of the company's stock, valued at approximately $2,042,000.

A number of other institutional investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $8,407,908,000. Proficio Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 100,387.1% during the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Capital International Investors lifted its holdings in shares of Eli Lilly and Company by 23.2% during the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after buying an additional 1,645,222 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $1,240,653,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

LLY stock traded up $0.01 on Thursday, reaching $719.40. 1,230,400 shares of the company were exchanged, compared to its average volume of 3,615,645. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock's fifty day moving average price is $782.03 and its 200 day moving average price is $801.29. The firm has a market capitalization of $681.80 billion, a PE ratio of 61.45, a PEG ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned $2.58 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.83%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on LLY shares. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.